glp 1 drugs in development GLP-1 Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom Long-term Success of GLP-1s Hinges
Description
doi:10.1007/s00125-008-1149-y Buteau J
The dual GIP/GLP-1 receptor agonist has shown superior efficacy in weight reduction and metabolic improvement, and its European rollout marks a significant milestone in expanding the availability of next-generation obesity drugs beyond the U.S
PD is characterized by bradykinesia, rigidity, and tremor [5]
Children: The recommended maintenance dose is 3 mg once daily
There are currently no FDA-approved GLP-1 receptor agonists that can be administered orally
doi: 10.1210/endo.136.11.7588224
